Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression
2009-014406-34Phase 2Active
- Sponsor
- ORVACS
- Start
- Nov 2009
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of recombinant human interleukin-7, maraviroc and raltegravir in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by ORVACS. Primary endpoint: Primary. Started Nov 2009; status: active.
02
Drugs
recombinant human interleukin-7maravirocraltegravir
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-014406-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014406-34.